

Maine Vaccine Board

2023 Calendar Year Assessment Calculation

Column →	A	B	C	D	E
Line ↓	2022		2023		
A. Preliminary Vaccine Cost, Projection Parameters, & Population Estimates					
01.	\$15,140,087		\$13,552,245		State Fiscal Year Vaccine Estimate (from tab b.)
02.	136,487		135,947		Estimate of Covered Lives (Covered Lives tab c.)
03.	\$151,401	1.0%	\$135,522	1.0%	Provision for Vaccine Utilization increase
04.	\$470,213	4.1%	\$369,570	3.6%	Vaccine cost inflation factor (prices change each April 1st)
05.	\$15,761,701		\$14,057,337		¹ Calendar Year Vaccine Funding Estimate
B. Budget Estimates					
06.	\$153,351		\$161,019		³ Servicing Agent Contract for Administrative Services
07.	\$7,350		\$7,500		Audit Fee (Move to paid public auditor)
08.	\$7,500		\$8,500		Bank Fees (adding TD Bank Lockbox including setup expenses)
09.	\$10,500		\$10,500		Legal (services of AG's office only estimated)
10.	\$178,701		\$187,519		Total Operating Costs Projected
C. Financial Carry Forwards					
11.	\$5,940,967		\$9,374,488		Estimated Starting Balance January 1
12.	\$3,800,499	3.0	\$7,151,547	6.54	Amount Retained for Liquidity Reserve - 3.0 months of non flu
13.	\$559,704		\$935,232		Amount Retained for Liquidity Reserve - full annual flu cost
14.	\$1,580,764		\$1,287,709		Carryforward used to reduce current assessment calculation
D. Aggregate Annual Assessment Calculation					
15.	\$15,761,701		\$14,057,337		Costs of Vaccines Provided
16.	\$178,701		\$187,519		Total Operating Costs
17.	\$0		\$0		Other (as approved by board -- see statute section 2.M)
18.	\$15,940,402		\$14,244,855		"Total Costs of the Fund" per statute section 2.M.
19.	\$55,791	0.35%	\$49,857	0.35%	Collection Losses (i.e. assumed "bad debt expense")
20.	-\$102,607		-\$80,039		² Interest Income
21.	-\$1,580,764	-9.9%	-\$1,287,709	-9.0%	(excess) or shortfall of cash from prior operating year
22.	\$557,914	3.50%	\$498,570	3.50%	add reserve up to 10% per statute section 5.A.(3).
23.	\$14,870,737		\$13,425,535		Total Assessments Needed
24.	-\$3,258,905		-\$3,855,292		Projected assessments February 15 at old rate
25.	\$11,611,832		\$9,570,243		Total Assessments Needed at new rate
E. Per Covered Life Assessment Calculation					
26.	\$113.44		\$93.86		Annual Assessment per Covered Life
27.	\$9.45		\$7.82		Monthly Assessment per Covered Life
28.	6.2%		-10.5%		% Change in Vaccine Costs
29.	18.8%		-17.3%		% Change in Assessment
30.			\$7.82		Issued Monthly Assessment per Covered Life
31.			-17.3%		Issued % Change in Assessment
F. Note: Total Assessed as % of Hard Vaccine Costs					
32.	-5.7%		-4.5%		All-in costs % above vaccine costs
G. Indicated Monthly Assessment Level next year apart from reserve / cash changes					
33.	\$10.48		\$9.57		⁴ Preliminary Assessment projection
Notes			22.3%		Increase in preliminary assessment projection

¹ Maine CDC + per vaccine adjustments + utilization increase with inflation factor.

² Used the average of FY20-FY22 Investment Income from audited financials.

³ Fixed price contract all inclusive of expenses.

⁴ Projection: annual amounts w/ carryforward cash, reserve changes, and 1 more year of inflation & utilization changes.

Maine CDC Vaccine Projection Data

Column →
Line ↓

	A	B	C	D	E	F	G	H	I	J	K
	Vaccine	Brand Name	NDC	Prior Year Actuals			Federal FY 23 Estimates			Federal FY 23 Estimates	Vaccine Funding Target
				Cost Per Dose	Doses	Cost	Cost Per Dose	Doses	Cost	Cost Per Dose	
01.	DAPTACEL	Sanofi Pastuer	49281-0286-10	\$ 19.20	2,859	\$ 54,893	\$ 19.88	3,221	\$64,033	0%	\$64,033
1.b				\$ 19.88	589	\$ 11,709.32					
02.	PENTACEL	Sanofi Pastuer	49281-0511-05	\$ 63.38	6,948	\$ 440,392.03	\$ 65.77	8,086	\$531,816	0%	\$531,816
2.b				\$ 65.77	1,707	\$ 112,269.39					
03.	QUADRACEL	Sanofi Pastuer	49281-0562-10	\$ 43.35	850	\$ 36,847.50	\$ 44.32	859	\$38,071	0%	\$38,071
3.b				\$ 44.32	69	\$ 3,058.08					
04.			49281-0564-15	\$ -	0	\$ -	\$ -	0	\$38,071	0%	\$0
4.b	IPOL (EIPV)	Sanofi Pastuer	49281-0860-10	\$ 14.06	2,643	\$ 37,160.58	\$ 15.11	3,108	\$46,971	0%	\$46,971
05.				\$ 15.11	419	\$ 6,332.35					
5.b	Menactra (MCV4)	Sanofi Pastuer	49281-0589-05	\$ 100.05	7,301	\$ 730,465.05					
06.				\$ 104.72	1,337	\$ 140,010.64					
	Medquadfi	Sanofi Pastuer	49281-0590-05	\$ 100.05	1,336	\$ 133,666.80	\$ 104.72	12,208	\$1,278,397	0%	\$1,278,397
07.				\$ 104.72	308	\$ 32,253.76					
7.b	ACTHIB (HIB)	Sanofi Pastuer	49281-0545-03	\$ 10.02	3,173	\$ 31,793.46	\$ 10.39	9,028	\$93,801	0%	\$93,801
08.				\$ 10.39	183	\$ 1,901.37					
8.b	ADACEL (Tdap)	Sanofi Pastuer	49281-0400-20	\$ 33.16	1,473	\$ 48,844.68	\$ 34.40	2,465	\$84,786	0%	\$84,786
09.				\$ 34.40	276	\$ 9,493.30					
9.b	TENIVAC	Sanofi Pastuer	49281-0215-15	\$ 21.77	148	\$ 3,221.96	\$ 22.58	279	\$6,300	0%	\$6,300
10.				\$ 22.58	50	\$ 1,129.00					
10.b	TRUMENBA (Menb)	Pfizer	00005-0100-10	\$ 119.93	895	\$ 107,337.35	\$ 125.77	364	\$45,780	0%	\$45,780
11.				\$ 125.77	47	\$ 5,911.19					
11.b	Prevnar 13 (PCV 13)	Pfizer	00005-1971-02	\$ 150.83	15,444	\$ 2,329,419	\$ 158.18	18,834	\$2,979,162	0%	\$2,979,162
11.c				\$ 158.18	4,151	\$ 656,605					
12.	Bexsero (Menb)	GlaxoSmithKline	58160-0976-20	\$ 128.60	1,513	\$ 194,572	\$ 135.00	4,692	\$633,406	0%	\$633,406
12.b				\$ 135.00	591	\$ 79,783					
12.c	MENVEO (MCV4)	GlaxoSmithKline	58160-0955-09	\$ 99.58	1,632	\$ 162,515	\$ 102.55	2,270	\$232,779	0%	\$232,779
13.				\$ 102.55	280	\$ 28,713					
13.b	Infanrix (DTaP)	GlaxoSmithKline	58160-0810-52	\$ 19.84	960	\$ 19,046	\$ 20.37	1,144	\$23,301	0%	\$23,301
13.c				\$ 20.37	265	\$ 5,398					
14.	Pediarix (DTaP/Hep B/IPV)	GlaxoSmithKline	58160-0811-52	\$ 62.49	2,857	\$ 178,534	\$ 62.49	3,104	\$193,975	0%	\$193,975
14.b				\$ 62.49	465	\$ 29,058					
15.	Kinrix (DTaP/IPV)	GlaxoSmithKline	58160-0812-52	\$ 43.64	2,990	\$ 130,484	\$ 45.27	3,735	\$169,080	0%	\$169,080
15.b				\$ 45.27	1,008	\$ 45,631					
15.c	Havrix (Hep A)	GlaxoSmithKline	58160-0825-52	\$ 21.72	7,738	\$ 168,069	\$ 22.35	14,498	\$324,074	0%	\$324,074
16.				\$ 22.35	2,232	\$ 49,885					
16.b	Engerix-B (Hep B)	GlaxoSmithKline	58160-0820-52	\$ 15.67	3,240	\$ 50,771	\$ 16.27	11,316	\$184,111	0%	\$184,111
16.c				\$ 16.27	1,024	\$ 16,660					\$0
17.	Rotarix (Rota)	GlaxoSmithKline	58160-0854-52	\$ 99.44	2,896	\$ 287,978	\$ 102.40	2,705	\$277,003	0%	\$277,003

Maine CDC Vaccine Projection Data

17.b			\$ 102.40	642	\$ 65,741							
18.	Boostrix (TDaP)	GlaxoSmithKline	58160-0842-52	\$ 34.07	4,676	\$ 159,311	\$ 35.02	7,975	\$279,300	0%	\$279,300	
18.b				\$ 35.02	982	\$ 34,390						
19.	HIBERIX	GlaxoSmithKline	58160-0818-11	\$ 9.62	23	\$ 221	\$ 10.10	62	\$626	0%	\$626	
19.b				\$ 10.11	0	\$ -						
19.c	VAQTA (Hep A)	Merck Sharp & Dohme Corp.	00006-4095-02	\$ 21.40	1,721	\$ 36,829	\$ 22.64	3,276	\$74,169	0%	\$74,169	
20.				\$ 22.64	532	\$ 12,044						
20.b	RECOMBIVAX (Hep B)	Merck Sharp & Dohme Corp.	00006-4981-00	\$ 13.00	2,172	\$ 28,236	\$ 13.55	7,417	\$100,500	0%	\$100,500	
21.				\$ 13.55	623	\$ 8,442						
21.b	PedvaxHib (Hib)	Merck Sharp & Dohme Corp.	00006-4897-00	\$ 13.79	2,780	\$ 38,336	\$ 14.82	8,616	\$127,689	0%	\$127,689	
22.				\$ 14.82	423	\$ 6,269						
22.b	Gardasil (HPV9)	Merck Sharp & Dohme Corp.	00006-4121-02	\$ 196.32	8,815	\$ 1,730,561	\$ 208.05	12,000	\$2,496,600	0%	\$2,496,600	
23.				\$ 208.05	1,921	\$ 399,664						
23.b	Vaxelis	Merck Sharp & Dohme Corp.	63361-0243-15	\$ 91.59	3,327	\$ 304,720	\$ 95.07	4,268	\$405,759	0%	\$405,759	
24.				\$ 95.07	1,242	\$ 118,077						
24.b	ROTATEQ (Rota)	Merck Sharp & Dohme Corp.	00006-4047-41	\$ 74.73	6,795	\$ 507,790	\$ 76.95	6,519	\$501,637	0%	\$501,637	
24.c				\$ 76.95	1,732	\$ 133,277						
24.d	MMR II	Merck Sharp & Dohme Corp.	00006-4681-00	\$ 22.11	4,679	\$ 103,453	\$ 23.67	5,634	\$133,357	0%	\$133,357	
25.				\$ 23.67	1,286	\$ 30,440						
26.	Proquad (MMRV)	Merck Sharp & Dohme Corp.	00006-4171-00	\$ 144.63	3,560	\$ 514,883	\$ 153.51	4,817	\$739,443	0%	\$739,443	
26.b				\$ 153.51	1,540	\$ 236,405						
27.	Pneumovax23 (Pedi)	Merck Sharp & Dohme Corp.	00006-4837-03	\$ 62.08	302	\$ 18,748	\$ 65.80	130	\$8,554	0%	\$8,554	
27.b				\$ 65.80	17	\$ 1,119						
28.	Varivax	Merck Sharp & Dohme Corp.	00006-4827-00	\$ 115.77	3,790	\$ 438,768	\$ 122.67	4,836	\$593,232	0%	\$593,232	
28.b				\$ 122.67	1,330	\$ 163,151						
29.	Fluzone PF 0.5ml (6mth+)	Sanofi Pasteur	49281-0422-50	\$ 14.25	24,000	\$ 342,000	\$ 14.25	24,000	\$342,000	0%	\$342,000	
29.b	FluMist Sprayer, 10-pack (2-18 y)	Astra Zeneca	66019-0309-10	\$ 18.88	3,500	\$ 66,080	\$ 18.88	3,500	\$66,080	0%	\$66,080	
30.	Flulaval PF 0.5ml (6mth+)	GlaxoSmithKline	19515-0808-52	\$ 14.66	32,500	\$ 476,450	\$ 14.66	32,500	\$476,450	0%	\$476,450	
31.				\$ -		\$ -						
32.				\$ -	0	\$ -				\$38,071		
33.				\$ -	0	\$ -						
34.						\$ 12,357,218			\$13,590,316	\$58.58	\$13,552,245	
35.	TOTAL			196,807	\$ 12,357,218		227,466	\$13,590,316			\$13,552,245	
36.											Adjusted for overall utilization increase	\$13,687,767
37.											Adjusted for price increase	\$14,057,337